Considering the enhanced effects of JAK inhibitors on skin inflammatory diseases and their potential to overcome resistance to androgen receptor-targeted therapy in prostate cancer, we hypothesize that the combination of JAK inhibitors and apalutamide may hold promise for prostate cancer treatment, but at present there are no clinical studies of this combination therapy, and it may be a logical direction to explore in the future. This evidence concerns the gene AR and prostate cancer.